Pro. Mbaya, kabla ya kuikana chanjo ya Korona ni vizuri ungeanzia na mile ambacho wewe umeifanyia dunia. Wengine tumeaanza kukusikia humu JF ukiwa na maandiko yako ya upande mmoja kama huu wa leo, upande wa kuunga mkono juhudi. Ili tukuamini ukisemacho weka hapa kumbukumbu yako hapa kuwa uliwahi kuishi duniani, mfano dawa ya kutibu jeraha la kuumwa na mende.
Kama hauna chochote basi jikite kwenye maswala ya CCM dhidi ya Chadema na ushindi mnono wa wizi wa kura, haya ya tiba yaache yapite kwani huu si uganga wenu wa kienyeji.
MKUU USIHANGAIKE SANA, PROF AJE HAPA ATUAMBIE KWENYE ENEO LA UTAFITI WA CHANJO KATI YA HAWA WAWILI TUMSIKILIZE YUPI KWA CV HIIZI WALIZO NAZO. MAANA HUYO MAMA CHINI NDIE ALIE SEMA CHANJO YA PFIZER-BIONTECH COVID-19 VACCINE IPO SALAMA KWA ASILIMIA 95.
Prof. Yunus Mgaya
Director-General, NIMR
Prof. Yunus Mgaya is Tanzanian, born in 1957. He studied at the University of Dar es Salaam, the University of British Columbia and the University College Galway in Ireland.
His research has focused mainly on coral reef fisheries, biology and management of invertebrate fisheries as well as aquaculture of different species. He is based at the University of Dar es Salaam, where he started out as a Tutorial Assistant and rose through the ranks to become a full Professor in 2006.
Over the years, Prof. Mgaya has gained wide administrative experience at the University and his recent achievements include his appointment as Associate Dean in the Faculty of Sicence (2000-2002), the Dean of Aquatic Sciences and Technology (2003-2006) and the Deputy Vice Chancellor in Charge of Planning, Finance and Administration (DVC-PFA) (2006-2014) and the Executive Secretary of the Tanzania Commission for Universities (TCU) (2014).
KATHRIN U. JANSEN, PH.D.
Senior Vice President, Head of Vaccine Research and Development
Dr. Jansen received her doctoral degree in microbiology, biochemistry & genetics from Phillips Universitaet, Marburg, Germany. Following completion of her formal training, she continued her postdoctoral training at Cornell University working on the structure and function of the acetylcholine receptor.
She then joined the Glaxo Institute for Molecular Biology in Geneva, Switzerland, where she focused on basic studies of a receptor believed to be a drug target to treat allergies. Dr. Jansen was appointed an Adjunct Professor at the University of Pennsylvania – School of Medicine in 2010.
Before the Wyeth acquisition by Pfizer in 2009, Dr. Jansen served as Senior Vice President at Wyeth Pharmaceuticals and on Wyeth’s Research and Development Executive Committee since 2006 and was responsible for vaccine discovery, early development and clinical testing operations.